Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 11/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.44 |
| ▸ | CDK2 | P24941 | 11/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.41 |
| ▸ | CDK1 | P06493 | 6/20 | 0.41 |
| ▸ | CDK4 | P11802 | 6/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.41 |
| ▸ | CCND1 | P24385 | 6/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.34 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963023 | 0.85 | CCNE2 (0.44) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL16724105 | 0.79 | SMN1; SMN2 (0.41) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL12292 | 0.76 | CCNE1 (0.59) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL9097022 | 0.75 | CA2 (0.45) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL16724117 | 0.73 | CCNE1 (0.44) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL2038320 | 0.72 | PTGS1 (0.38) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL16086926 | 0.70 | CDK2 (0.49) | CCNE2CCNE1CDK2PTGS1CCNB2 | |
| SCHEMBL10594957 | 0.70 | PTGS1 (0.40) | PTGS1CXCR1CXCR2HSD17B10GSTP1 | |
| SCHEMBL9627350 | 0.70 | PTGS1 (0.40) | PTGS1CXCR1CXCR2HSD17B10GSTP1 | |
| SCHEMBL970491 | 0.69 | PTGS1 (0.39) | CCNE2CCNE1CDK2PTGS1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880673-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| EP-3880673-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113015730-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CCNE2 4837/4885CCNE1 4866/4885CDK2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.